The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...

A groundbreaking randomized clinical trial led by Chair of Radiation Oncology Daniel Spratt at University Hospitals Seidman ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate cancer. The international study, published in The New England Journal of ...

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...

For men with a localized recurrence following prostate cancer radiotherapy, salvage treatment with either focal therapy or surgery may offer comparable long-term cancer control, but focal therapy ...

Add Yahoo as a preferred source to see more of our stories on Google. Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to compare ...